PROVIGIL and NUVIGIL become the latest branded medicines to be sold in the United States within the Apotex Group's diversified global portfolio of products.
The submission leverages a recently completed front-end engineering design (FEED) study and includes an assessment of the project's expected carbon intensity using the Fuel Life Cycle Assessment Model ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback